"Dihydroergotamine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.
| Descriptor ID |
D004087
|
| MeSH Number(s) |
D03.132.327.412.225 D03.633.400.562.300
|
| Concept/Terms |
DHE-45- DHE-45
- DHE 45
- DHE45
- D.H.E. 45
Dihydroergotamine Mesylate- Dihydroergotamine Mesylate
- Mesylate, Dihydroergotamine
- Dihydroergotamine Methanesulfonate
- Methanesulfonate, Dihydroergotamine
Migranal- Migranal
- Dihydergot
- Dihydroergotamine-Sandoz
- Dihydroergotamine Sandoz
|
Below are MeSH descriptors whose meaning is more general than "Dihydroergotamine".
Below are MeSH descriptors whose meaning is more specific than "Dihydroergotamine".
This graph shows the total number of publications written about "Dihydroergotamine" by people in this website by year, and whether "Dihydroergotamine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 2003 | 2 | 1 | 3 |
| 2006 | 2 | 1 | 3 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 2 | 2 | 4 |
| 2011 | 3 | 0 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2023 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dihydroergotamine" by people in Profiles.
-
Tepper SJ, Albrecht D, Ailani J, Kirby L, Strom S, Rapoport AM. Long-Term (12-Month) Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine: Data from the Phase 3 Open-Label ASCEND Study. CNS Drugs. 2024 12; 38(12):1017-1027.
-
Wang VS, Kosman J, Yuan H, Lauritsen C, Shrewsbury S, Aurora SK, Hopkins M, Silberstein S. Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study. Headache. 2023 10; 63(9):1251-1258.
-
Tepper SJ, Ailani J, Ray S, Hirman J, Shrewsbury SB, Aurora SK. Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure. J Headache Pain. 2022 Nov 22; 23(1):148.
-
Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - Then and Now: A Narrative Review. Headache. 2020 01; 60(1):40-57.
-
Chua AL, Silberstein S. Inhaled drug therapy development for the treatment of migraine. Expert Opin Pharmacother. 2016 Sep; 17(13):1733-43.
-
Tepper SJ. Orally inhaled dihydroergotamine: a review. Headache. 2013 Sep; 53 Suppl 2:43-53.
-
Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013 May; 27(5):385-94.
-
Silberstein S. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine. Expert Opin Pharmacother. 2012 Sep; 13(13):1961-8.
-
Tepper SJ, Kori SH, Borland SW, Wang MH, Hu B, Mathew NT, Silberstein SD. Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia. Headache. 2012 Jan; 52(1):37-47.
-
Tepper SJ, Kori SH, Goadsby PJ, Winner PK, Wang MH, Silberstein SD, Cutrer FM. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc. 2011 Oct; 86(10):948-55.